4//SEC Filing
GILEAD SCIENCES, INC. 4
Accession 0001123292-25-000510
$GILDCIK 0001426800operating
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 4:30 PM ET
Size
11.1 KB
Accession
0001123292-25-000510
Insider Transaction Report
Form 4
GILEAD SCIENCES, INC.
10% Owner
Transactions
- Purchase
Class A warrants to purchase Common Stock
2025-08-08+1,147,960→ 1,147,960 totalExercise: $21.60→ Common Stock (1,147,960 underlying) - Purchase
Common Stock
2025-08-08+2,295,920→ 4,505,391 total - Purchase
Class B warrants to purchase Common Stock
2025-08-08+1,147,960→ 1,147,960 totalExercise: $21.60From: 2026-11-15Exp: 2026-12-31→ Common Stock (1,147,960 underlying)
Footnotes (3)
- [F1]Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.
- [F2]The Class A Warrants are exercisable at any time after the date of issuance and expire on the earlier of (i) five years from the date of issuance, or August 11, 2030, and (ii) the date that is 30 days after the public announcement that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. A holder of the Class A Warrants may not exercise the Class A Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
- [F3]The Class B Warrants are exercisable at any time after November 15, 2026 and expire on December 31, 2026, provided that the Class B Warrants will automatically terminate in full and be extinguished and will no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that the Issuer has received at least $75 million in the aggregate of non-dilutive capital in connection with a collaboration agreement. A holder of the Class B Warrants may not exercise the Class B Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Issuer
ASSEMBLY BIOSCIENCES, INC.
CIK 0001426800
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000882095
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 4:30 PM ET
- Size
- 11.1 KB